Physician profile
David C Urrate
NPI 1598872871
$18,186.10
in general payments reported to CMS, 2019-2025
32 companies · $3,232 in 2025
The $3,232 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,813 · 2020: $1,032 · 2021: $2,672 · 2022: $2,520 · 2023: $2,959 · 2024: $2,958 · 2025: $3,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,135 · Education: $14.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,135.00 |
| Education | $14.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,370.53 | 2020-2025 | Caplyta |
| Alkermes, INC. | $2,323.29 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,986.89 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,794.51 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,598.70 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,029.06 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $945.00 | 2019-2022 | |
| Corium, LLC | $724.80 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $688.78 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $644.58 | 2019-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $637.40 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $626.32 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $461.22 | 2019-2025 | Spravato |
| Allergan, INC. | $433.74 | 2019-2020 | |
| Neos Therapeutics, LP | $418.18 | 2019-2024 | Adzenys Xr-Odt |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $240.57 | 2019 | |
| Collegium Pharmaceutical, INC. | $180.45 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $163.34 | 2023-2025 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $142.33 | 2019-2021 | |
| Tris Pharma INC | $137.41 | 2022-2024 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $133.46 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $108.12 | 2022-2023 | Qelbree |
| Eisai INC. | $87.09 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $72.76 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $72.76 | 2023-2024 | Quviviq |
| Adlon Therapeutics L.P. | $46.73 | 2019-2020 | |
| Alfasigma USA, INC. | $31.51 | 2022 | |
| Acadia Pharmaceuticals INC | $27.18 | 2025 | Nuplazid |
| Tms Neurohealth Centers INC. | $15.93 | 2025 | Tms Neurohealth Centers INC. |
| Vertical Pharmaceuticals, LLC | $15.70 | 2019 | |
| Biogen, INC. | $14.24 | 2024 | |
| Rhodes Pharmaceuticals L.P. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Urrate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.